Latest Peregrine Pharmaceuticals Inc (PPHM) Headlines
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Marketwire - Tue Mar 11, 3:11PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced that its Board of Directors has declared a quarterly cash dividend on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").
Just How Important Is Bavituximab to Peregrine Pharmaceuticals?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 11, 1:10PM CDT
Only within the biotech sector can you find a waltz between hope and science. Over the past year and change, biotech stocks have been red hot. There were were 38 biotech IPOs in 2013, and collectively that group rose by an astounding 43% for the...
Loss Widens at Peregrine, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:40AM CDT
Peregrine Pharma reported a net loss of 6 cents per share in the third quarter of fiscal 2014.
Data Presentations at Keystone Symposium Support Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies to Overcome Immune Suppression and Enhance Anti-Tumor Activity of Anti-CTLA-4 and PD-1 Antibodies
Marketwire - Tue Mar 11, 7:04AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that preclinical data presentations made validate the immune-stimulatory mechanism of its phosphatidylserine (PS) targeting platform while demonstrating that the combination of an anti-PS antibody and anti-CTLA-4 or anti-PD-1 antibody displayed superior tumor growth than either anti-CTLA-4 or anti-PD-1 antibody alone in animal tumor models. These data were outlined in two presentations at the Keystone Immune Evolution in Cancer meeting being held March 9-13, 2014 in Whistler, British Columbia, Canada. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
Peregrine Pharmaceuticals (PPHM) Marked As A Dead Cat Bounce Stock
at The Street - Mon Mar 10, 8:45AM CDT
Trade-Ideas LLC identified Peregrine Pharmaceuticals (PPHM) as a "dead cat bounce" (down big yesterday but up big today) candidate
Skullcandy and Foot Locker are big market movers
AP - Fri Mar 07, 3:30PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
Why Peregrine Pharmaceuticals, Inc. Shares Tumbled
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 07, 11:53AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Peregrine Pharmaceuticals , a...
Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
at The Street - Fri Mar 07, 9:49AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2014 Financial Results and Recent Developments
Marketwire - Fri Mar 07, 7:01AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on the development of first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced financial results for the third quarter of fiscal year (FY) 2014 ended January 31, 2014 and provided an update on its advancing clinical pipeline and other corporate developments.
Most active Nasdaq-traded stocks
AP - Thu Mar 06, 5:07PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Look for Shares of Peregrine Pharmaceuticals to Potentially Pullback after Yesterday's 47.64% Rise
Comtex SmarTrend(R) - Wed Mar 05, 5:40PM CST
Peregrine Pharmaceuticals (NASDAQ
PHM) traded in a range yesterday that spanned from a low of $1.98 to a high of $2.88. Yesterday, the shares gained 47.6%, which took the trading range above the 3-day high of $1.92 on volume of 36.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
3 Stocks Making Massive 1-Day Moves
David Williamson, The Motley Fool - Motley Fool - Wed Mar 05, 4:52PM CST
In the biotech space today, three stocks made absolutely massive moves, with each popping or dropping by more than 20% in a single day. First up is Peregrine , the day's biggest winner by far, up nearly 50% today on the announcement that it would...
Why Peregrine Pharmaceuticals, Arrowhead Research, and Maxwell Technologies Are Today's 3 Best Stock
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 05, 4:15PM CST
Following yesterday's surge to a new record high close by the S&P 500 , investors have to be quite pleased with the tight trading range and minor dip in the iconic index today despite mixed economic data. On the bright side, the latest...
Why Peregrine Pharmaceuticals Inc. Shares Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 05, 1:44PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Peregrine Pharmaceuticals , a developer of...
Pre-Market Review of Top Gainers: Canadian Solar, Qihoo 360 Technology, Peregrine Pharma, Renren, and UTi Worldwide
PR Newswire - Wed Mar 05, 9:40AM CST
Editor Note: For more information about this release, please scroll to bottom.
2 Biotech Stocks Under $10 to Trade
at The Street - Wed Mar 05, 5:00AM CST
Keep these under-$10 biotech stocks on your radar.
Peregrine Pharmaceuticals PS-Targeting Immunotherapy Platform to Be Highlighted in Three Data Presentations at Keystone Symposia Conferences
Marketwire - Tue Mar 04, 3:00PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced the presentation of data from three preclinical studies highlighting the immuno-oncology and anti-viral potential of phosphatidylserine (PS)-targeting antibodies at two upcoming Keystone Symposia to be held March 9-13, 2014. Bavituximab, the company's lead immunotherapy candidate, is advancing in a Phase III SUNRISE trial for the treatment of second-line non-small cell lung cancer.
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Marketwire - Tue Mar 11, 3:11PM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced that its Board of Directors has declared a quarterly cash dividend on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").
Just How Important Is Bavituximab to Peregrine Pharmaceuticals?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 11, 1:10PM CDT
Only within the biotech sector can you find a waltz between hope and science. Over the past year and change, biotech stocks have been red hot. There were were 38 biotech IPOs in 2013, and collectively that group rose by an astounding 43% for the...
Loss Widens at Peregrine, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:40AM CDT
Peregrine Pharma reported a net loss of 6 cents per share in the third quarter of fiscal 2014.
Data Presentations at Keystone Symposium Support Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies to Overcome Immune Suppression and Enhance Anti-Tumor Activity of Anti-CTLA-4 and PD-1 Antibodies
Marketwire - Tue Mar 11, 7:04AM CDT
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that preclinical data presentations made validate the immune-stimulatory mechanism of its phosphatidylserine (PS) targeting platform while demonstrating that the combination of an anti-PS antibody and anti-CTLA-4 or anti-PD-1 antibody displayed superior tumor growth than either anti-CTLA-4 or anti-PD-1 antibody alone in animal tumor models. These data were outlined in two presentations at the Keystone Immune Evolution in Cancer meeting being held March 9-13, 2014 in Whistler, British Columbia, Canada. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) as part of the SUNRISE pivotal Phase III clinical trial.
Peregrine Pharmaceuticals (PPHM) Marked As A Dead Cat Bounce Stock
at The Street - Mon Mar 10, 8:45AM CDT
Trade-Ideas LLC identified Peregrine Pharmaceuticals (PPHM) as a "dead cat bounce" (down big yesterday but up big today) candidate
Skullcandy and Foot Locker are big market movers
AP - Fri Mar 07, 3:30PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
Why Peregrine Pharmaceuticals, Inc. Shares Tumbled
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 07, 11:53AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Peregrine Pharmaceuticals , a...
Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
at The Street - Fri Mar 07, 9:49AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2014 Financial Results and Recent Developments
Marketwire - Fri Mar 07, 7:01AM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), a biopharmaceutical company focused on the development of first-in-class monoclonal antibodies for the treatment and diagnosis of cancer, today announced financial results for the third quarter of fiscal year (FY) 2014 ended January 31, 2014 and provided an update on its advancing clinical pipeline and other corporate developments.
Most active Nasdaq-traded stocks
AP - Thu Mar 06, 5:07PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Look for Shares of Peregrine Pharmaceuticals to Potentially Pullback after Yesterday's 47.64% Rise
Comtex SmarTrend(R) - Wed Mar 05, 5:40PM CST
Peregrine Pharmaceuticals (NASDAQ
PHM) traded in a range yesterday that spanned from a low of $1.98 to a high of $2.88. Yesterday, the shares gained 47.6%, which took the trading range above the 3-day high of $1.92 on volume of 36.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. 3 Stocks Making Massive 1-Day Moves
David Williamson, The Motley Fool - Motley Fool - Wed Mar 05, 4:52PM CST
In the biotech space today, three stocks made absolutely massive moves, with each popping or dropping by more than 20% in a single day. First up is Peregrine , the day's biggest winner by far, up nearly 50% today on the announcement that it would...
Why Peregrine Pharmaceuticals, Arrowhead Research, and Maxwell Technologies Are Today's 3 Best Stock
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 05, 4:15PM CST
Following yesterday's surge to a new record high close by the S&P 500 , investors have to be quite pleased with the tight trading range and minor dip in the iconic index today despite mixed economic data. On the bright side, the latest...
Why Peregrine Pharmaceuticals Inc. Shares Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 05, 1:44PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Peregrine Pharmaceuticals , a developer of...
Pre-Market Review of Top Gainers: Canadian Solar, Qihoo 360 Technology, Peregrine Pharma, Renren, and UTi Worldwide
PR Newswire - Wed Mar 05, 9:40AM CST
Editor Note: For more information about this release, please scroll to bottom.
2 Biotech Stocks Under $10 to Trade
at The Street - Wed Mar 05, 5:00AM CST
Keep these under-$10 biotech stocks on your radar.
Peregrine Pharmaceuticals PS-Targeting Immunotherapy Platform to Be Highlighted in Three Data Presentations at Keystone Symposia Conferences
Marketwire - Tue Mar 04, 3:00PM CST
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced the presentation of data from three preclinical studies highlighting the immuno-oncology and anti-viral potential of phosphatidylserine (PS)-targeting antibodies at two upcoming Keystone Symposia to be held March 9-13, 2014. Bavituximab, the company's lead immunotherapy candidate, is advancing in a Phase III SUNRISE trial for the treatment of second-line non-small cell lung cancer.
